CCS
DGX icon

Crosspoint Capital Strategies’s Quest Diagnostics DGX Stock Holding History

Crosspoint Capital Strategies’s Portfolio DGX Stock Details DGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-1,300
Closed -$92K – 269
2015
Q4 		$92K Buy
1,300
+200
+18% +$13.4K 0.02% 351
2015
Q3 		$68K Sell
1,100
-1,300
-54% -$90.9K 0.08% 222
2015
Q2 		$174K Buy
2,400
+1,300
+118% +$96K 0.05% 210
2015
Q1 		$85K Sell
1,100
-2,600
-70% -$186K 0.04% 220
2014
Q4 		$248K Buy
3,700
+2,600
+236% +$164K 0.09% 170
2014
Q3 		$67K Sell
1,100
-300
-21% -$18.5K 0.05% 188
2014
Q2 		$87K Buy
+1,400
New +$82K 0.03% 206

Other funds holding DGX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $123B AUM 45.23% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
BA
BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
DSA
Davis Selected Advisers Tucson, Arizona $23.3B AUM 26.95% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Crosspoint Capital Strategies's DGX Position: Q1 2016 in Review

Crosspoint Capital Strategies sold out of Quest Diagnostics (DGX) in Q1 2016, closing a stake of 1,300 shares — an estimated $92K sold.

Crosspoint Capital Strategies first reported a position in DGX in Q2 2014 and held it in 7 quarters. The position peaked at $248K in Q4 2014. 557 funds tracked by Wall St. Rank hold DGX as of Q1 2016.

  • Crosspoint Capital Strategies reported no remaining Quest Diagnostics position as of Q1 2016 after selling out during the quarter.
  • Crosspoint Capital Strategies sold 1,300 Quest Diagnostics shares in Q1 2016, an estimated $92K.
  • Crosspoint Capital Strategies first reported a position in Quest Diagnostics in Q2 2014 and held it in 7 quarters.
  • Crosspoint Capital Strategies's Quest Diagnostics position peaked at $248K in Q4 2014.
  • 557 funds tracked by Wall St. Rank held Quest Diagnostics as of Q1 2016.

Based on Crosspoint Capital Strategies's 13F filing for Q1 2016, filed 16 May 2016.